Genmab A/S (GMAB) Stock Overview
Explore Genmab A/S’s financial performance, market position, analyst ratings, and future outlook.
Genmab A/S (GMAB)
Key Financials
Key Financials
Market Cap
23.2B
P/E Ratio
29.71
EPS (TTM)
$1.33
ROE
0.14%
GMAB Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Genmab A/S (NASDAQ: GMAB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Genmab A/S's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of GMAB on the NASDAQ shows an RSI of 67.89, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $30.90 for the NASDAQ listing.
Key metrics behind Genmab A/S's NASDAQ-traded stock include a P/E ratio of 29.71 and a market capitalization of 23.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GMAB on the NASDAQ.